Patent Term Extension Application for XOLREMDI™ (mavorixafor), Patent No. 11,219,621 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2024-E-3590

Patent Term Extension Application for XOLREMDI™ (mavorixafor), Patent No. 11,219,621

Documents

Comments

Description

Open

Comment Period OpensAug 9, 2024

Comment Period ClosesAug 16, 2025

Type	Title	Posted	Comments	Status
Other	Letter from FDA CDER to U.S. Patent and Trademark Office	Apr 22, 2026	--

CDER

Patent Term Extension Application

Patent No. 11,219,621

XOLREMDI™ (mavorixafor)

X4 Pharmaceuticals, Inc.

Dechert LLP

Open